Herceptin Package Insert

ALPROLIX Package Insert - Food And Drug Administration
Provided in the ALPROLIX package. 8. With one hand, hold the diluent syringe by the ridged part directly under the cap, with the 10. With the vial sitting on a flat surface, insert the tip of ... Visit Document

NEW ZEALAND DATA SHEET Herceptin (trastuzumab)
For full instructions on assay performance and interpretation please refer to the package inserts of validated FISH, CISH and SISH assays. Official recommendations on HER2 testing may also apply. Breast Cancer Herceptin treatment is only appropriate if there is strong HER2 overexpression, as described by a 3+ score ... Fetch This Document

1.14.1.3 Final Labeling Text Initial Dose Of 4 Mg/kg As A 90 ...
Herceptin may be resumed if, within 4−8 weeks, the LVEF returns to normal limits and the absolute decrease from baseline is ≤ 15%. Permanently discontinue Herceptin for a persistent ( > 8 weeks) LVEF decline or for suspension of Herceptin dosing on more than 3 occasions for cardiomyopathy. ... Document Viewer

HIGHLIGHTS OF PRESCRIBING INFORMATION - Genentech
• Do not substitute Herceptin (trastuzumab) for or with ado-trastuzumab emtansine. Adjuvant Treatment, Breast Cancer . Administer according to one of the following doses and schedules for a total of 52 weeks of Herceptin therapy: During and following paclitaxel, docetaxel, or docetaxel/carboplatin: • ... Fetch Here

Talk:Michael Milken/Archives/2013 - Wikipedia
Bert Vogelstein, MD, who received a Milken Family Foundation Cancer Research Award in 1988, and leveraged that award to garner additional funding allowing him to help develop Herceptin, which now treats breast cancer, might also have a different opinion. ... Read Article

Taxotere Prescribing Information - Home - Sanofi
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use TAXOTERE safely and effectively. See full prescribing information for TAXOTERE. ... Read Content

HIGHLIGHTS OF PRESCRIBING INFORMATION ...
Page 3 of 35 FULL PRESCRIBING INFORMATION WARNING: LEFT VENTRICULAR DYSFUNCTION and EMBRYO-FETAL TOXICITY • Left Ventricular Dysfunction: PERJETA can result in subclinical and clinical cardiac failure manifesting as decreased LVEF and CHF. ... Access Document

NEW ZEALAND DATA SHEET Herceptin SC (trastuzumab)
NEW ZEALAND DATA SHEET Herceptin SC (trastuzumab) Herceptin SC 180501 1 1. PRODUCT NAME Herceptin SC 600mg/5mL 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Herceptin SC vial contains 600mg/5mL of trastuzumab. For the full list of excipients, see section 6.1. ... Access Doc

Herceptin® (trastuzumab) - Moda Health
Herceptin will be administered intrathecally Gastric, Esophageal and Esophagogastric Junction Cancers † Herceptin [package insert]. South San Francisco, CA; Genentech, Inc; April 2017. Accessed August 2018. 2. Referenced with permission from the NCCN Drugs & Biologics Compendium (NCCN ... Get Content Here

HERCEPTIN (trastuzumab) - Provider.carefirst.com
Herceptin is indicated, in combination with cisplatin and capecitabine or 5-fluorouracil, for the treatment of patients with HER2 overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma, who have not received prior treatment for metastatic disease. ... Retrieve Content

HIGHLIGHTS OF PRESCRIBING INFORMATION Experiencing ... - NERLYNX
FULL PRESCRIBING INFORMATION. 1 INDICATIONS AND USAGE . NERLYNX is indicated for the extended adjuvant treatment of adult patients with early stage HER2- ... Read Full Source

1.14.1.3 Final Labeling Text Initial Dose Of 8 Mg/kg Over 90 ...
Herceptin is indicated, in combination with cisplatin and capecitabine or 5-fluorouracil, for the treatment of patients with HER2 overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma, who have not received prior treatment for metastatic disease. ... View This Document

Herceptin® (trastuzumab) - EmblemHealth
HERCEPTIN® (trastuzumab) Prior Auth Criteria Proprietary Information. Restricted Access – Do not disseminate or copy without approval. ©2017, Magellan Rx Management VII. References 1. Herceptin [package insert]. South San Francisco, CA; Genentech, Inc; April 2017. Accessed October 2017. 2. ... Get Content Here

SPECIALTY GUIDELINE MANAGEMENT - Nhp.org
Reference number(s) 1905-A SPECIALTY GUIDELINE MANAGEMENT . HERCEPTIN (trastuzumab) OGIVRI (trastuzumab-dkst) POLICY . I. INDICATIONS . The indications below including FDA-approved indications and compendial uses are considered a covered ... Fetch Doc

Herceptest™ Interpretation Manual - Breast Cancer
HercepTestTM Interpretation Manual – Breast Cancer ROW Version 6 HER2 Protein and HER2 Family considered (see Herceptin® package insert). For breast cancer patient, results from the . HER2 IQFISH pharmDx™ Kit are intended for use as an ... Retrieve Content

HIGHLIGHTS OF PRESCRIBING INFORMATION Interstitial Lung ...
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use HYCAMTIN FOR INJECTION safely and effectively. ... Retrieve Full Source

HERCEPTIN (trastuzumab) - Caremark
Exposure to Herceptin during pregnancy can result in oligohydramnios, in some cases complicated by pulmonary hypoplasia and neonatal death (1). Safety and effectiveness in pediatric patients have not been established (1). Summary Herceptin (trastuzumab) is a monoclonal antibody that selectively binds with high affinity to the HER2 protein. ... Doc Retrieval

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
Herceptin intravenous infusion should be administered by a health-care provider prepared to manage anaphylaxis and an emergency kit should be available. Patients should be observed for at least six hours after the start of the first infusion and for two hours after the ... Document Retrieval

HIGHLIGHTS OF PRESCRIBING INFORMATION CONTRAINDICATIONS ...
With trastuzumab and docetaxel were di TM not listed. HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use ... Retrieve Document

WARNINGS AND PRECAUTIONS------------------------ Decreases In ...
Saquinavir, telithromycin, voriconazole). Grapefruit may also increase plasma concentrations of lapatinib and should be avoided. If patients must be coadministered, a strong CYP3A4 inhibitor, based on pharmacokinetic studies, a dose reduction to 500 mg/day of lapatinib is predicted to adjust the lapatinib AUC to the range ... Content Retrieval